Can pregnant women use Sarilumab?

Sarilumab is a drug used to treat moderate to severe rheumatoid arthritis, a disease that causes inflammation of the joints. It is used when treatment with one or more drugs called disease-modifying antirheumatic drugs (DMARDs) is not effective enough or causes troublesome side effects. It is used together with methotrexate (DMARD), but can also be used alone if the patient cannot take methotrexate.

The monoclonal antibody salirumab is actively transported across the placenta during late pregnancy and may affect the immune response of the infant exposed in utero. Consistent with the mechanism of action, animal data suggest that fetuses/infants of treated mothers may have reduced IgG levels in response to antigenic challenge. In an animal reproduction study, including a comprehensive study of embryo-fetal and prenatal and postnatal development in monkeys receiving intravenous administration of salirumab, there was no evidence that exposure to doses up to approximately 84 times the maximum recommended human dose (MRHD) resulted in embryotoxicity or fetal malformations. The literature suggests that inhibition of IL-6 signaling may interfere with cervical ripening and dilation and myometrial contractile activity, leading to potential delays in labor.

The patent drug Thalilutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.